Related Experiment Videos
Combination chemotherapy (CYVADIC) in metastatic soft tissue sarcomas
European Journal of Cancer & Clinical Oncology
|January 1, 1982
Summary
The CYVADIC chemotherapy regimen showed a 27% response rate in metastatic sarcoma patients. Surgical removal of partially regressed tumors may improve survival outcomes in these patients.
Area of Science:
- Oncology
- Medical Chemotherapy
Background:
- Metastatic sarcoma presents a significant treatment challenge.
- Effective chemotherapy regimens are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of the CYVADIC chemotherapy regimen in patients with metastatic sarcoma.
- To assess the impact of surgical intervention on outcomes for patients with partial tumor regression.
Main Methods:
- Forty-one patients with metastatic sarcoma received Adriamycin, Cyclophosphamide, Vincristine, and Dacarbazine (CYVADIC).
- Response rates, disease stabilization, and progression were monitored.
- Surgical excision of regressed nodules was performed in a subset of patients.
Main Results:
- The CYVADIC regimen achieved a combined response rate of 27% (3 complete, 8 partial regressions).
- Disease stabilization occurred in 8 patients, while 22 experienced progression.
- Four patients undergoing surgical excision of partially regressed tumors remained alive at a median follow-up of 24.5 months.
Conclusions:
- CYVADIC demonstrates moderate efficacy in metastatic sarcoma.
- Surgical removal of residual disease following chemotherapy may enhance long-term survival.